 |
|||
 |
 |
 |
|
PRO 140
Blocking HIV cellular entry: PRO 140
We recently completed a phase 1b study of PRO 140 to explore the safety and efficacy of PRO 140 following a single intravenous dose in HIV-1 infected individuals. In May 2007, we announced positive results from this study that established clear proof of concept that the PRO 140 humanized monoclonal antibody was a potent antiretroviral agent with extended activity. In this single-dose study, PRO 140 produced highly significant reductions in viral load and suppressed viral replication for two to three weeks.
PRO 140 has been granted Fast Track designation by the FDA.